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Abstract
Background: Subarachnoid hemorrhage (SAH) is a devastating disease that affects over 30,000 Americans per year.
Previous animal studies have explored the therapeutic effects of deferoxamine (DFX) via its iron-chelating properties
after SAH, but none have assessed the necessity of microglial/macrophage heme oxygenase-1 (HO-1 or Hmox1)
in DFX neuroprotection, nor has the efficacy of an intracerebroventricular (ICV) administration route been fully
examined. We explored the therapeutic efficacy of systemic and ICV DFX in a SAH mouse model and its effect on
microglial/macrophage HO-1.
Methods: Wild-type (WT) mice were split into the following treatment groups: SAH sham + vehicle, SAH + vehicle,
SAH + intraperitoneal (IP) DFX, and SAH + ICV DFX. For each experimental group, neuronal damage, cognitive
outcome, vasospasm, cerebral and hematogenous myeloid cell populations, cerebral IL-6 concentration, and
mitochondrial superoxide anion production were measured. HO-1 co-localization to microglia was measured
using confocal images. Trans-wells with WT or HO-1−/− microglia and hippocampal neurons were treated with
vehicle, red blood cells (RBCs), or RBCs with DFX; neuronal damage, TNF-α concentration, and microglial HO-1
expression were measured. HO-1 conditional knockouts were used to study myeloid, neuronal, and astrocyte
HO-1 involvement in DFX-induced neuroprotection and cognitive recovery.
Results: DFX treatment after SAH decreased cortical damage and improved cognitive outcome after SAH yet
had no effect on vasospasm; ICV DFX was most neuroprotective. ICV DFX treatment after SAH decreased cerebral IL-6
concentration and trended towards decreased mitochondrial superoxide anion production. ICV DFX treatment after
SAH effected an increase in HO-1 co-localization to microglia. DFX treatment of WT microglia with RBCs in
the trans-wells showed decreased neuronal damage; this effect was abolished in HO-1−/− microglia. ICV DFX
after SAH decreased neuronal damage and improved cognition in Hmox1fl/fl control and NesCre:Hmox1fl/fl mice,
but not LyzMCre:Hmox1fl/fl mice.
Conclusions: DFX neuroprotection is independent of vasospasm. ICV DFX treatment provides superior neuroprotection
in a mouse model of SAH. Mechanisms of DFX neuroprotection after SAH may involve microglial/macrophage
HO-1 expression. Monitoring patient HO-1 expression during DFX treatment for hemorrhagic stroke may help
clinicians identify patients that are more likely to respond to treatment.
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Background
Over 30,000 Americans will fall victim to an aneurysmal
subarachnoid hemorrhage (SAH) this year; nearly half of
these patients will die within 6 months [1, 2]. Of those
SAH survivors, approximately 50 % will develop severe
cognitive and functional deficits [3, 4]. Although the ma-
jority of research in SAH has focused on the treatment
of vasospasm, only nimodipine has been shown to im-
prove outcome [5, 6]. Multiple clinical trials have dem-
onstrated that even when vasospasm was effectively
treated, morbidity and mortality were not ameliorated
[7–9]. These studies suggest that neurological injury can
be vasospasm-independent. Further research aimed at
mitigating this heme-induced cerebral inflammatory re-
sponse is required [10].
In SAH, the heme from blood spilled into the sub-
arachnoid space is metabolized by heme oxygenase
(HO), generating excess free iron [11]. This iron is hy-
pothesized to enable cell membrane damage via free rad-
icals [12] with studies showing a causal relationship
between unbound iron and brain injury following SAH
[13]. Deferoxamine (DFX), an iron-chelating agent, has
been shown to be neuroprotective in various hemorrhagic
models via several mechanisms [12, 14]. Previous stud-
ies using a rat model of SAH showed decreased brain
edema, oxidative stress, and neuronal apoptosis after
DFX treatment [15, 16]. However, none of these studies
assess the necessity of heme oxygenase-1 (HO-1 or
Hmox1) in DFX neuroprotection nor has the efficacy of
intracerebroventricular administration been fully exam-
ined. Our lab previously showed microglia to be critical
in red blood cell-induced neuroinflammation [10], and
most recently, we found microglial HO-1 to be neuro-
protective after SAH in a mouse model [17]. We hy-
pothesized that microglial/macrophage HO-1 is critical
for DFX neuroprotection and that intracerebroventricular
administration would provide superior neuroprotection in
a mouse model of SAH.
We undertook the current set of experiments to first com-
pare the effects of systemic versus intracerebroventricular
injection of DFX on neuronal damage, vasospasm, pro-
inflammatory and oxidative biomarkers, and immune
cell populations in a mouse model of SAH; second, to
see if microglial/macrophage HO-1 is sufficient for
DFX neuroprotection; and third, to compare the effects
of cell-specific HO-1 knockouts on DFX neuroprotec-
tion and cognitive outcome. Our study provides a plat-
form for the potential translation of DFX treatment
into the SAH patient population.
Methods
Animal information and anesthesia
All experimental procedures were approved by the
Institutional Animal Care and Use Committee
(IACUC) of Beth Israel Deaconess Medical Center
(BIDMC). The facility is accredited by the Association
for Assessment and Accreditation of Lab Animal Care
and fully complied with all Federal, State and Local
Law. Animals were housed at BIDMC and fed a stand-
ard rodent diet ad libitum with 24-h access to either
water and/or hydrogel while kept on a 12-h light/12-h
dark cycle. All surgical manipulations were performed
under general anesthesia with ketamine (10 mg/kg)
and xylazine (4 mg/kg), and buprenorphine (50 μg/kg)
was systemically administered. All mice used were
male on a C57BL/6 background (The Jackson Labora-
tory). Cell-specific HO-1 knockout in myeloid cells
(LyzMCre:Hmox1fl/fl) and astrocytes and neurons
(NesCre:Hmox1fl/fl) was achieved as previously de-
scribed by our lab [17]. All mice had similar fur color
and were approximately the same size and weight. The
average mouse weight was 25 g (0.025 kg) with a
weight range of 24 g (0.024 kg) to 27 g (0.027 kg).
Wild-type (WT) mice were randomly assigned between
the following four treatment groups equally: WT sub-
arachnoid hemorrhage (SAH) sham + intraperitoneal
(IP) normal saline (NS) + intracerebroventricular
(ICV) NS (SAH sham + vehicle), WT SAH + IP NS +
ICV NS (SAH + vehicle), WT SAH + IP deferoxamine
(DFX) + ICV NS (SAH + IP DFX), and WT SAH + IP
NS + ICV DFX (SAH + ICV DFX). Lab personnel per-
forming surgical procedures were not the same as
those performing cognitive assays to allow for appro-
priate blinding.
SAH
The method used to induce SAH has been previously
tested and validated in a mouse model [18]. After the
mice were anesthetized with xylazine (10 mg/kg) and
ketamine (12 mg/kg), SAH was performed as previ-
ously described by our lab using a standard stereotaxic
instrument set-up (KOPF Instruments, Tujunga, CA,
USA) [17]. To open the skin overlying the anterior
skull, a midline incision was performed. Then, a burr
hole was drilled into the anterior skull, 4.5 mm anter-
ior to the bregma. Sixty microliters of autologous
blood from a C57BL/6 wild-type blood donor mouse
was injected over a 10-s period with a 27-gauge needle
at a 40° caudal angle into the drilled burr hole. The
needle was left in place for 5 min to prevent backflow
of blood.
Intracerebroventricular injection of deferoxamine
After the mice were anesthetized, intracerebroventricular
injection was performed using a standard stereotaxic
instrument set-up (KOPF Instruments, Tujunga, CA,
USA). One burr hole was drilled 0.22 mm posterior to
the bregma, 1 mm lateral, and 2.25 mm in depth to
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enter the ventricle. On SAH POD1, 24 h after the in-
duced SAH, a single, non-repeated injection of 8 mg/kg
of DFX was administered using pre-measured capillaries.
Dosing was chosen based on dose-tolerance data gener-
ated by our lab (Table 1).
Intraperitoneal injection of deferoxamine
Starting on SAH POD1, 24-h after the induced SAH,
the mice were given systemic injections of 200 mg/kg
of DFX every morning, 30 min prior to cognitive test,
until euthanization on SAH POD7. Dosage was chosen
based on a previous publication testing systemic deferox-
amine treatment in another mouse model of hemorrhagic
stroke [19].
TUNEL
All in vivo imaging was taken on SAH sham or SAH
post-operative day (POD) 7 due to our lab’s previous
publication showing SAH POD7 to have the most
significant hippocampal cell damage [10]. Brain sections
and HT-22 cells were stained with terminal deoxynu-
cleotidyl transferase dUTP nick end labeling (TUNEL;
Roche Life Science, Indianapolis, IN, USA). Slides were
covered using Vectashield mounting medium with DAPI
(Vector Laboratories, Burlingame, CA, USA) for nuclear
counterstaining. HT-22 cells were counterstained with
Hoechst 33258 (Sigma-Aldrich, Natick, MA, USA). Lab
personnel interpreting TUNEL stains were not aware of
the groups to which they were assigned.
H&E
Coronal brain sections were stained with hematoxylin
and eosin (H&E) (Poly Scientific R&D Corp., Bay Shore,
NY, USA). The middle cerebral artery (MCA) lumen ra-
dius/wall thickness ratio was quantified using ImageJ
software (NIH). Lab personnel interpreting H&E stains
were not aware of the groups to which they were
assigned.
Confocal imaging
Eight-micrometer coronal brain sections from each
experimental group were post-fixed and permeabilized,
followed by being blocked with 10 % donkey serum. The
sections were then stained with the following primary
antibodies: goat anti-Iba1 (1:500) and rabbit anti-HO-1
(1:500) to identify HO-1 expression and HO-1 co-
localization to microglia. The sections were then stained
with the following secondary antibodies: donkey anti-
goat 488 (1:250) and donkey anti-rabbit 594 (1:250). The
sections were then counterstained with nuclei marker
DAPI and sealed. The sections were viewed and images
were taken on a Zeiss confocal microscope. Layers of
images from the most anterior to the most posterior
portion were taken, and a Z-stack image was created.
ImageJ software was used for co-localization cell count-
ing as well as co-localization heat maps. Co-localization
percentage per high-powered field for each experimental
group’s confocal Z-stacked images was obtained by div-
iding the total number of yellow-positive by the total
number of DAPI-positive cells. Co-localization histo-
grams were generated using the coloc-2 feature of Ima-
geJ software. In brief, the program combines the green
HO-1 single channel-1 saturation pixels with the red
Iba-1/microglia single channel-2 saturation pixels to
calculate the level at which they overlap. The x-axis rep-
resents channel-1 pixel intensity, while the y-axis repre-
sents channel-2 pixel intensity. Blue represents the
lowest population frequency possible while yellow repre-
sents the highest. The lower the slope for each heat
map, the more HO-1 staining there is per Iba-1/micro-
glia staining.
ELISA
Whole brain lysates were equally loaded onto a 96-well
plate and cerebral IL-6 concentration was determined
using ELISA Max Biolegend kit per manufacturer’s
instructions. Media from microglia-neuron trans-well
experiments were equally loaded onto a 96-well plate
and culture TNF-α concentration was determined using
ELISA Max Biolegend kit per manufacturer’s instruc-
tions (Biolegend, San Diego, CA, USA).
Flow cytometry
All flow cytometry acquisition was performed on a
FACSCalibur (BD Biosciences, San Jose, CA, USA), and
analysis was completed using FlowJo software (FlowJo,
LLC, Ashland, OR, USA). Cells were isolated from whole
brain or blood and re-suspended in FACS buffer (1 %
bovine albumin, 2 mM ethylenediaminetetraacetic acid
(EDTA), and 0.05 % NaN3 in phosphate-buffered saline
(PBS)). To block unspecific sites, the cells were first
stained with CD16/32 Trustain (1:100; Biolegend, San
Diego, CA, USA). The cells were then washed with
FACS buffer and stained with the following fluorescent-
tagged antibodies: PE-Gr-1 and PeCy7-CD11b (1:100;
Biolegend, San Diego, CA, USA). To identify the
Table 1 Intracerebroventricular deferoxamine dose-tolerance
chart
ICV dose Total mice tested Tolerance
0.8 mg/kg (~0.02 mg per mouse) 3 Well tolerated
8 mg/kga (~0.2 mg per mouse) 3 Well tolerated
80 mg/kg (~2 mg per mouse) 2 Immediately died
Wild-type mice were injected with a one-time intracerebroventricular (ICV)
dose of deferoxamine diluted in normal saline, to test how well each dose
would be tolerated
aThe highest dose tolerated was chosen for all experimental procedures
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myeloid cell populations in the blood and brain, CD45+
cells were gated off of a CD45/SSC-H dot plot. Then,
using a Gr-1/CD11b dot plot, macrophages were identi-
fied as CD11bhi/Gr-1lo while neutrophils were
CD11bhiGr-1hi (Additional file 1: Figure S1). To measure
the total mitochondrial superoxide anion production,
whole brain cell lysates were incubated with MitoSOX
red mitochondrial superoxide indicator per manufac-
turer’s instructions (5 μM; Life Technologies/Thermo-
Fisher, Cambridge, MA, USA) and cells positive in the
FL-2 channel were reported. Appropriate unstained con-
trols for each channel were used to determine stained
cell populations.
Primary microglia and neuronal HT-22 cells—trans-wells
Microglia cells were isolated from the brains of neonatal
mice using the Neural Tissue Dissociation Kit (P) (Miltenyi
Biotec, Cambridge, MA, USA). The resulting mixed glia
culture, containing astrocytes and microglia, was cultivated
in media containing macrophage-colony stimulating
factor (M-CSF). After 1 week of cultivation, the micro-
glia were collected and grown on 3-μm cell culture in-
serts (EMD Millipore, Billerica, MA, USA). Murine
hippocampal neuronal HT-22 cells were grown on six-
well plates in normal media without M-CSF. For trans-
well assays, the inserts with microglia were placed on
top of the HT-22 neuron wells; microglia and HT-22
neuronal cells shared media during experiments. A
total of 200 μl of whole blood was collected from the
submandibular vein of a wild-type donor mouse and
placed into 10 ml of PBS to keep the blood from clot-
ting. The whole blood in PBS was then centrifuged at
2000 rpm for 5 min. The plasma, leukocyte, and plate-
let layers were aspirated, leaving an erythrocyte pellet.
The erythrocytes were washed in an additional 10 ml of
PBS and centrifuged at 2000 rpm for 5 min. The super-
natant was aspirated and the erythrocyte pellet was re-
suspended in 2 ml of PBS; 100 μl of this RBC suspension
in PBS was added to the top microglia-containing cham-
ber of the microglia-neuron trans-well; after 1-h of blood
exposure, DFX (100 μM) or vehicle was added to the
microglia chamber, and an additional hour of incubation
was completed.
Western blot
Primary microglial cell lysates were equally loaded onto a
polyacrylamide gel and transferred to an immune-blot
PVDF membrane (Bio-Rad, Hercules, CA, USA). Mem-
branes were blocked with 5 % milk and stained with rabbit
HO-1 antibody (1:1000, Abcam, Cambridge, MA, USA)
and mouse vinculin antibody (1:1000, Sigma-Aldrich,
Natick, MA, USA).
Morris water maze
Cognitive performance was assessed using the Morris
water maze as previously described, with minor modifi-
cations made by our lab [17]. In brief, after 7 days of ac-
quisition, SAH sham or SAH was performed. On the day
of SAH sham or SAH surgical procedure, the mice were
not tested on the Morris water maze. The mice resumed
testing on the Morris water maze on POD1. The mice to
be treated with DFX were then either given daily IP
DFX injections starting on POD1 and ending on POD7
or a one-time ICV injection of DFX on POD1. Addition-
ally, mice that received daily IP DFX injections also got
a one-time ICV injection of NS on POD1, and the mice
that received a one-time ICV DFX injection also got
daily IP NS injections from POD1 to POD7. SAH sham
or SAH mice that were not treated with DFX, each re-
ceived daily IP NS from POD1 to POD7 and a one-time
injection of ICV NS on POD1 (Table 2). Spatial memory
testing, measured by time to reach goal platform and
consisting of 1-trial in the morning per animal per day,
was started on SAH POD1 and continued for 7-days.
On SAH POD4, the goal platform was moved to the op-
posite side of the maze (spatial reversal), while visual cue
locations were unchanged. An investigator blinded to
treatment groups performed the maze procedures.
Statistical analysis
Multiple experimental groups were compared using
repeated-measures two-way ANOVA with Bonferroni’s
post hoc test for in vivo TUNEL staining and HO-1/Iba1
co-localization of multiple brain regions, and the results
are presented as the mean ± SD (GraphPad Prism).
Morris water maze data was presented as the mean ±
SEM (GraphPad Prism) and analyzed using repeated-
measures two-way ANOVA with Bonferroni’s post hoc
test. For all other statistical comparisons, multiple ex-
perimental groups were compared using one-way
ANOVA with Bonferroni’s post hoc test, and the results
are presented as the mean ± SD (GraphPad Prism). Dif-
ferences were considered significant at P < 0.05.
Study approval
All procedures involving animals were approved by the
IACUC and the Radiation Safety Office (RSO) of Beth
Israel Deaconess Medical Center.
Results
Intracerebroventricular deferoxamine injection
dose-tolerance in wild-type mice
In order to determine the dose of DFX to be injected
into the intracerebroventricular (ICV) space, a dose-
tolerance chart was generated using WT mice (Table 1).
Since 8 mg/kg was the highest dose tested that was well
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tolerated by the mice, this dose was chosen for further
experimental procedures.
Degree of deferoxamine neuroprotection and cognitive
improvement after SAH depends on drug administration
route and is vasospasm-independent
All mice used had similar size and weight and appeared
otherwise healthy prior to any surgical procedure. The
WT mice were randomly assigned between the follow-
ing four treatment groups: subarachnoid hemorrhage
(SAH) sham + vehicle, SAH + vehicle, SAH + intraper-
oteneal (IP) DFX, and SAH + ICV DFX (Table 2).
Neuronal damage and vasospasm were assessed for all
of the treatment groups on POD7, based on our previ-
ous work [10]; cognitive outcome was assessed on
POD1–7 using the Morris water maze (Fig. 1a–g). The
SAH + vehicle mice had significantly increased cortical
and hippocampal cellular damage compared to the
SAH sham + vehicle mice, while the SAH + IP DFX
mice and SAH + ICV DFX mice had markedly de-
creased cortical and hippocampal damage as compared
to the SAH mice (ANOVA P < 0.05; P < 0.05 between
groups; n = 5; Fig. 1b, c). The one-time ICV DFX injec-
tion decreased cortical and hippocampal damage to a
greater extent than daily IP DFX injections (P < 0.05
versus SAH + IP DFX; Fig. 1b, c). Differences in cogni-
tive outcome arose between the treatment groups on
POD4, 5, and 7. The SAH + ICV DFX treatment group
resulted in better cognitive performance than the SAH
+ vehicle and SAH + IP DFX groups on POD4 and the
SAH + vehicle group on POD5. Additionally, both DFX
treatment groups after SAH improved cognitive function
when compared to the SAH + vehicle group on POD7
(ANOVA P < 0.05; P < 0.05 between groups; n = 5; Fig. 1d).
Although the SAH + group had a significantly lower
lumen radius to wall thickness (LR/WT) of the middle
cerebral artery (MCA) than the SAH sham + vehicle
group, DFX treatment had no effect on this SAH-induced
MCA vasospasm (ANOVA P < 0.05; P < 0.05 SAH sham +
vehicle versus SAH + vehicle; n = 5; Fig. 1f, g).
Next, we determined whether or not DFX had an
effect on cerebral and hematogenous myeloid cell popu-
lations; it did not (n = 4; Fig. 2a, b). Subsequently, we
measured the effects of DFX on cerebral inflammatory
milieu after SAH on POD7 by quantifying interleukin
(IL)-6 and mitochondrial superoxide anion in whole
brain lysates. In the SAH + vehicle group, cerebral IL-6
production was increased as compared to control
(ANOVA P < 0.05; P < 0.05 versus SAH sham + vehicle;
n = 4; Fig. 2c); ICV DFX treatment markedly decreased
the concentration of cerebral IL-6 after SAH while IP
DFX did not (P < 0.05 versus SAH + vehicle; n = 4;
Fig. 2c). Additionally, the SAH + vehicle group had in-
creased mitochondrial superoxide anion production as
compared to the control (ANOVA P < 0.05; P < 0.05 ver-
sus SAH sham + vehicle; n = 4; Fig. 2d, e), and while not
statistically significant, there was a trend towards de-
creased mitochondrial superoxide anion in the SAH +
ICV DFX treatment group as compared to the SAH +
vehicle group (n = 4; Fig. 2d, e).
Microglial HO-1 is sufficient for deferoxamine
neuroprotection in an in vitro model
To determine if DFX treatment of microglia was suffi-
cient to reduce neuronal damage, we performed in vitro
trans-well assays with WT microglia and hippocampal
neuronal HT-22 cells. WT microglia incubated with red
blood cells (RBCs) for 2 h demonstrated marked neur-
onal damage by the trans-well assay (ANOVA P < 0.05;
P < 0.05 versus control; n = 3; Fig. 3a, b). Additionally,
there was a trend towards increased TNF-α production
in the trans-well assays incubated with RBCs (ANOVA
Table 2 Wild-type experimental mouse groups






Mice received subarachnoid hemorrhage (SAH), sham surgical procedure, daily
intraperoteneal (IP) injections of normal saline (NS) starting on post-operative
day (POD) 1 and ending on POD7, and a one-time intracerebroventricular






Mice received SAH surgical procedure, daily IP injections of NS starting on






Mice received SAH surgical procedure, daily IP injections of deferoxamine
(DFX) starting on POD1 and ending on POD7, and a one-time ICV injection






Mice received SAH surgical procedure, daily IP injections of NS starting on
POD1 and ending on POD7, and a one-time ICV injection of DFX on POD1.
Wild-type (WT) mice were randomly assigned between the four treatment groups listed in the table. Each mouse was exposed to all surgical procedures and
injections as specified in the explanation. The abbreviation listed in the table was used throughout the results including figures and figure legends
for simplicity.
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P < 0.05; n = 3; Fig. 3b). RBC-induced neuronal damage
was significantly reduced when DFX was added 1 h after
RBC exposure began, for a total RBC exposure of 2 h
(P < 0.05 versus RBC only exposure; n = 3; Fig. 3a, b).
Further, there was a trend towards decreased TNF-α
production in the trans-well assays treated with DFX after
RBC exposure (n = 3; Fig. 3b). To determine if the HO-1
pathway in microglia was involved, we repeated the trans-
Fig. 1 Deferoxamine provides vasospasm-independent neuroprotection and improves cognitive outcome after subarachnoid hemorrhage—
cortical and hippocampal damage, cognitive outcome, and middle cerebral artery (MCA) vasospasm were measured in the following treatment
groups in wild-type (WT) mice: subarachnoid hemorrhage (SAH) sham + vehicle, SAH + vehicle, SAH + intraperitoneal (IP) deferoxamine (DFX),
and SAH + intracerebroventricular (ICV) DFX. a Image stained with DAPI (magenta) located at the anterior hippocampus. b Representative TUNEL
(red) stained images of cortical and hippocampal sections from each treatment group with DAPI (blue) nuclei counterstain on post-operative day
(POD) 7 (scale bar = 20 μm). c Quantification of TUNEL-positive cells for each group. The least amount of cortical and hippocampal damage was
seen in the SAH + ICV DFX group followed by the SAH + IP DFX group. (Two-way ANOVA P < 0.05; *P < 0.05; n = 5 per group). d Morris water
maze testing of WT mice cognitive outcome for each group. Inset, bar graph of data for POD4, 5, and 7 show the SAH + ICV DFX mice performed
significantly better than the SAH + vehicle group on POD4 and 5 and significantly better than the SAH + IP DFX on POD4. Both SAH + IP DFX
and SAH + ICV DFX groups performed significantly better than SAH + vehicle mice on POD7 (two-way ANOVA P < 0.05; *P < 0.05; n = 5 per
group). e Image stained with hematoxylin and eosin (H&E) located adjacent to the anterior hippocampus. f Representative H&E stained images
of MCA from each group on POD7 (scale bar = 10 μm). g Quantification of MCA vasospasm measured by lumen radius/wall thickness (LR/WT)
quotient. DFX did not decrease vasospasm seen in the SAH + vehicle group (one-way ANOVA P < 0.05; *P < 0.05 SAH sham + vehicle versus
SAH + vehicle; n = 5 per group)
LeBlanc et al. Journal of Neuroinflammation  (2016) 13:244 Page 6 of 15
well experiment using HO-1−/− microglia. In the trans-
well assays with HO-1−/− microglia, neuronal damage and
TNF-α production was notably increased in trans-wells
exposed to RBCs for 2 h (ANOVA P < 0.05; P < 0.05 versus
control; n = 3; Fig. 3c, d). But unlike the WT microglia
trans-wells, RBC-induced neuronal damage was not
significantly reduced in neurons underlying HO-1−/−
microglia when DFX was added (n = 3; Fig. 3c, d). Further,
Fig. 2 ICV DFX reduces cerebral inflammatory milieu after SAH—hematogenous and cerebral myeloid cell populations, cerebral IL-6 concentration,
and cerebral mitochondrial superoxide anion were measured in the following treatment groups on POD7 in WT mice: SAH sham + vehicle, SAH +
vehicle, SAH + IP DFX, and SAH + ICV DFX. a Flow cytometry of hematogenous cell populations show no significant change between any of the
groups (one-way ANOVA; n = 4 per group). b Flow cytometry of cerebral myeloid cell populations show a trend towards increase in the microglia/
macrophage populations of the SAH + vehicle group versus the SAH sham + vehicle group; but no significant changes between any of the other groups
(one-way ANOVA; n= 4 per group). c Cerebral IL-6 concentration as measured by ELISA was significantly increased in the SAH + vehicle group (*P< 0.05
versus the SAH sham + vehicle group) and markedly decreased in the SAH + ICV DFX group (*P< 0.05 versus the SAH + vehicle group) (one-way ANOVA
P< 0.05; n= 4 per group). d Cerebral mitochondrial superoxide anion (MitoSox) positive cells measured by flow cytometry did not show significant
decrease in the SAH + ICV DFX group versus the SAH + vehicle group and the SAH + IP DFX group (one-way ANOVA P < 0.05; n = 4 per group).
e Representative flow cytometry dot plots from each group. The Q3 percentage (shown) represents the percentage of cells positive for MitoSOX red
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TNF-α concentrations remained markedly elevated in
assays with HO-1−/− microglia after DFX addition to the
RBC-treated trans-wells (n = 3; Fig. 3d).
Next, we sought to determine why the loss of micro-
glial HO-1 diminished the neuroprotective effects of
DFX. First, we measured the HO-1 protein expression in
primary microglial lysates exposed to vehicle, RBCs, or
RBCs with DFX. There was increased HO-1 protein ex-
pression in the microglia treated with RBCs and DFX as
compared to vehicle (ANOVA P < 0.05; P < 0.05 versus
control; n = 3; Fig. 3e, f ).
Intracerebroventricular deferoxamine increases in vivo
microglia and HO-1 co-localization
We wanted to validate the results we observed in our in
vitro model, in vivo. That is, we wanted to examine
whether ICV DFX increased microglial HO-1 expression
in our in vivo SAH model. To see if DFX caused an in-
crease in microglia and HO-1 co-localization, we took
Z-stacked confocal images of brain sections adjacent to
the anterior hippocampus, stained for microglia (Iba-1
positive) and HO-1 of all four of our in vivo experimen-
tal groups (Table 2). HO-1 co-localization to microglial
Fig. 3 Microglial HO-1 has a role in deferoxamine protection from red blood cell (RBC)-induced neuronal damage—Trans-wells with WT or HO-1−/−
primary microglia were plated with hippocampal neurons (HT-22) and treated with vehicle, red blood cells (RBCs), or RBCs with DFX.
a Representative TUNEL (red) stained images of neurons from each WT primary microglia trans-well with DAPI (blue) nuclei counterstain (all scale bars
= 20 μm). b Quantification of TUNEL-positive neurons and TNF-α concentration from each WT primary microglia trans-well; RBC exposure significantly
increased neuronal damage while DFX significantly reduced this RBC-induced damage (one-way ANOVA P < 0.05; *P < 0.05; n = 3 per group). Trend
towards increased TNF-α production in the trans-well assays incubated with RBCs (one-way ANOVA P < 0.05; n = 3; b); trend towards decreased TNF-α
production in the trans-well assays treated with DFX after RBC exposure (n = 3; b). c TUNEL stained images of neurons from each HO-1−/− primary
microglia trans-well with DAPI nuclei counterstain. d Quantification of TUNEL-positive neurons and TNF-α concentration from each HO-1−/− primary
microglia trans-well; RBC exposure significantly increased neuronal damage as well as TNF-α production, and DFX did not reduce this RBC-induced
damage or TNF-α concentration (one-way ANOVA P < 0.05; *P < 0.05; n = 3 per group). e Western blot of primary microglial lysates from each group.
f Quantification of bands from Western blot of primary microglial lysate; showed that HO-1 protein expression significantly increased in WT primary
microglia culture exposed to RBCs with DFX (one-way ANOVA P < 0.05; *P < 0.05; n = 3 per group)
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cells on these in vivo sections from lowest to highest
was as follows: SAH sham + vehicle, SAH + vehicle,
SAH + IP DFX, and SAH + ICV DFX (ANOVA P < 0.05;
P < 0.05 between groups; n = 3; Fig. 4a–c).
Microglial/macrophage HO-1 is critical to intracerebroven-
tricular deferoxamine neuroprotection and cognitive
improvement after SAH
We performed SAH on LyzMCre:Hmox1fl/fl mice lacking
microglial, neutrophil, and all other myeloid HO-1 as
well as in NesCre:Hmox1fl/fl mice lacking neuronal and
astrocyte HO-1 and Hmox1fl/fl control mice and mea-
sured the amount of HO-1 co-localization to microglia
in each. LyzMCre:Hmox1fl/fl SAH mice showed the least
HO-1/Iba-1 co-localization percentage in both the cor-
tex and hippocampus as compared to Hmox1fl/fl and
NesCre:Hmox1fl/fl SAH mice on POD7 (two-way ANOVA
P < 0.05; P < 0.05 between groups; n = 4; Fig. 5a, b). We
then performed SAH and subsequent ICV DFX treat-
ment on LyzMCre:Hmox1fl/fl, NesCre:Hmox1fl/fl, and
Hmox1fl/fl control mice. ICV DFX-treated LyzMCre:H-
mox1fl/fl mice after SAH showed significant cortical and
hippocampal damage on POD7 as compared to ICV
DFX treated Hmox1fl/fl SAH controls, while ICV DFX
treated NesCre:Hmox1fl/fl mice after SAH did not
(ANOVA P < 0.05; P < 0.05 between groups; n = 4; Fig. 5c,
d). Cognitive protection of ICV DFX after SAH was
tested on Hmox1fl/fl, LyzMCre:Hmox1fl/fl, and NesCre:H-
mox1fl/fl mice. The LyzMCre:Hmox1fl/fl mice performed
markedly worse than the Hmox1fl/fl control mice
(ANOVA P < 0.05; P < 0.05 between groups for POD5
and 7; n = 4 Fig. 5e) while NesCre:Hmox1fl/fl mice per-
formed just as well as Hmox1fl/fl control mice and sig-
nificantly better than LyzMCre:Hmox1fl/fl mice (P < 0.05;
P < 0.05 between groups for POD5 and 7; n = 4 Fig. 5e).
Discussion
In a mouse model of SAH, we found that DFX exerted
neuroprotective effects by non-canonical mechanisms.
(1) DFX improved cognitive outcomes and reduced cere-
bral damage, independent of vasospasm. (2) ICV DFX
was the most neuroprotective. (3) ICV DFX decreased
neuroinflammatory markers. (4) Microglial HO-1 is suf-
ficient for DFX neuroprotection in an in vitro model of
blood-induced inflammation. (5) ICV DFX neuroprotec-
tion and cognitive improvement is dependent on micro-
glial/macrophage HO-1.
The iron-chelating agent, DFX, has been tested for thera-
peutic use in many animal neurological disease models in-
cluding Huntington’s disease [20], traumatic brain injury
[21–23], cerebral ischemia [24–26], and hemorrhagic
stroke among others. DFX has been extensively studied in
animal models of intraventricular hemorrhage (IVH) and
intracerebral hemorrhage (ICH). In IVH animal models,
DFX reduced ventricular enlargement, brain damage,
and markers of post-hemorrhagic chronic hydroceph-
alus [27–31]. In ICH animal models, DFX has been
shown to reduce brain damage [32–37], decrease neu-
roinflammation [34, 38–40], and improve cognitive
outcome [38, 41]. Further, DFX was shown to reduce
DNA damage [37, 40], oxidative stress [32, 33, 38],
neuronal hemoglobin expression [42], and autophagy
markers [43], following ICH. Additionally, in a germi-
nal matrix hemorrhage model of neonatal rats, DFX
reduced brain damage, ventricular dilation, and improved
cognitive outcome [44].
Although DFX treatment has also been studied in
SAH animal models, experiments using DFX treatment
specifically in a mouse model of SAH are lacking. In rat
models of SAH, DFX has been shown to decrease overall
mortality, edema, oxidative stress, and neuronal death
[15, 16]. Additionally, DFX treatment after SAH has
been shown to decrease cortical apoptotic markers [16]
and reduce markers of brainstem damage in rats [45],
as well as reduce lipid peroxidation markers and im-
prove sodium-potassium ATPase activity in guinea pigs
[46]. Our study looked to further elucidate the mecha-
nisms of DFX-induced neuroprotection in a mouse
model of SAH.
In our current study, administration of DFX after
induction of SAH in our mouse model was effective in
reducing the cerebral inflammatory response. DFX ad-
ministered via two different routes, reduced cortical and
hippocampal damage after SAH on POD7; the greatest
reduction was seen with ICV DFX, followed by IP DFX
(Fig. 1b, c). Further, both IP and ICV DFX treatment im-
proved cognitive outcome during a later phase of SAH
POD7, but only ICV DFX treated mice showed early im-
provement on POD4 and 5. Although DFX administra-
tion effectively reduced brain damage (Fig. 1b, c) and
improved cognitive outcome (Fig. 1d) after SAH, it had
no effect on vasospasm (Fig. 1f, g). These results were
interesting for two reasons. First, the IP dose of DFX is
25-fold greater than the ICV dose, and yet the ICV dose
showed more neuroprotection and earlier cognitive im-
provement. A potential explanation is that ICV adminis-
tration allows for proximity to the heme burden, while
IP-administered DFX has to effectively cross the blood
brain barrier. Second, DFX provided cerebral protection
and improved cognition after SAH independent of any ef-
fect on vasospasm, similar to previous studies that showed
DFX treatment had no effect on vascular response after
SAH [47, 48]. Vasospasm-independent cerebral protection
provided by DFX is not surprising when one considers re-
cent clinical trials that effectively treated vasospasm but
did not improve morbidity or mortality after SAH [7, 8].
DFX has been previously shown to have anti-
inflammatory effects in hemorrhagic stroke [14]. We
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investigated whether these anti-inflammatory effects
might be partly mediated by changes in immune cell
populations, cerebral IL-6 concentration, or mitochon-
drial superoxide anion production. The SAH + vehicle
group showed an upward trend in the cerebral micro-
glial/macrophage cell population as compared to the
SAH sham + vehicle group, but DFX did not signifi-
cantly reduce this increase. Cerebral neutrophils and
hematogenous populations of macrophages and neutro-
phils remained unchanged with DFX administration
(Fig. 2a, b). Further, SAH caused a significant increase
in both cerebral IL-6 concentrations and mitochondrial
superoxide production as compared to sham; in the
ICV DFX-treated group, cerebral IL-6 concentrations
were reduced and a trend towards decreased reduction
in mitochondrial superoxide production was present
(Fig. 2c–e). These results indicate that ICV DFX may
partially exert protective effects not by changing the total
number of microglia/macrophage cells, but instead via
modulation of the pro-inflammatory mechanics of these
cells, while systemic DFX injection does not.
We investigated whether DFX neuroprotection was
dependent on microglia using a microglia-neuron trans-
well assay. These assays revealed that DFX offered pro-
tection against red blood cell (RBC) induced neuronal
damage, even when DFX was added to microglia after
RBC exposure had already begun (Fig. 3a, b). When we
repeated these trans-well assays with HO-1−/− microglia,
DFX offered no neuroprotection (Fig. 3c, d). Addition-
ally, we found that DFX treatment increased the protein
expression of HO-1 in primary microglial culture (Fig. 3e,
f ). These results suggest that microglial HO-1 is critical
to the mechanism of DFX neuroprotection, possibly, in
part, by facilitating the increased expression of micro-
glial HO-1. Our lab has previously shown that adminis-
tration of carbon monoxide (CO) rescues the neuronal
injury seen in co-cultures with HO-1−/− microglia [17].
This indicates that the neuroprotective product of heme
breakdown via microglial HO-1 in the context of
microglia-neuron co-cultures is CO. Since this current
work shows microglial HO-1 to be increased following
DFX treatment, it is likely that increased CO production
may be involved. Additionally, DFX would chelate the
excess iron from heme breakdown, potentially leading to
synergistic benefits produced by DFX administration: in-
creased CO protection and decreased iron toxicity.
When we looked at confocal images of all of our ex-
perimental groups, we found that SAH markedly in-
creased the co-localization of microglia and HO-1
compared to sham. Further, we found that ICV DFX
treatment affected a significant increase in HO-1 expres-
sion within microglia while IP DFX did not (Fig. 4a–c).
Because these results demonstrated that ICV DFX most
effectively increased microglial HO-1 expression in vivo,
we next sought to ascertain the necessity of microglial
HO-1 for ICV DFX neuroprotection. Mice lacking mye-
loid HO-1 (LyzMCre:Hmox1fl/fl) and mice lacking neur-
onal and astrocyte HO-1 (NesCre:Hmox1fl/fl) were
exposed to SAH and then treated with ICV DFX. Inter-
estingly, ICV DFX treatment after SAH protected the
NesCre:Hmox1fl/fl mice similarly to the Hmox1fl/fl. Con-
versely, LyzMCre:Hmox1fl/fl mice showed significantly
more neuronal damage and cognitive dysfunction com-
pared to Hmox1fl/fl mice (Fig. 5c–e). This, together with
the in vitro data, supported the hypothesis that myeloid
HO-1, but not astrocyte or neuronal HO-1, was critical
for ICV DFX to reduce brain damage and improve cog-
nition after SAH.
It is still not completely clear why the lack of mye-
loid HO-1 would suppress DFX neuroprotection in
vivo, but we speculate that the DFX mediated in-
crease in myeloid HO-1 cannot occur in the myeloid
HO-1 knockout (LyzMCre:Hmox1fl/fl) mice. Without
the increased myeloid HO-1 expression, the subse-
quent increase in neuroprotective CO production
would be absent. In our previous work, we showed
that the neuronal damage and cognitive dysfunction
seen in LyzMCre:Hmox1fl/fl mice could be saved by ad-
ministering external CO, showing that CO was the
neuroprotective byproduct of myeloid HO-1 heme
breakdown [17]. Since our current in vitro data sug-
gests that microglial HO-1 is crucial for DFX neuro-
protection, it is possible that increased myeloid HO-1
expression in vivo, due to DFX administration, could
(See figure on previous page.)
Fig. 4 ICV DFX treatment after SAH causes an increase in HO-1/microglia co-localization—Confocal Z-stacked images were taken of the following
treatment groups on POD7 in WT mice: SAH sham + vehicle, SAH + vehicle, SAH + IP DFX, and SAH + ICV DFX. a Representative confocal images
of each experimental group. All images were taken adjacent to the anterior hippocampus, which can be visualized by the DAPI merged image at
the bottom right tile. Each color represents the following: green = HO-1; red = Iba-1/microglia; yellow = overlap of green and red/co-localization of
HO-1 and microglia; blue = DAPI nuclei counterstain. All scale bars = 20 μm. b Co-localization heat maps for each experimental group. The x-axis
represents channel-1 (HO-1) pixel intensity, while the y-axis represents channel-2 (Iba-1) pixel intensity. Blue represents the lowest population
frequency possible while yellow represents the highest. The lower the slope for each heat map, the more HO-1 staining there is per Iba-1/microglia
staining. c The percent quantification of co-localization per high-powered field for each experimental group’s confocal Z-stacked images.
Co-localization percentage was obtained by dividing the total number of yellow-positive cells by the total number of DAPI-positive cells.
The highest HO-1/Iba-1 co-localization percentage was seen in the SAH + ICV DFX group, followed by the SAH + IP DFX and SAH + vehicle
group (one-way ANOVA P < 0.05; *P < 0.05; n = 3 per group)
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cause increased CO production and thus result in
better protection. Further experimentation would be
necessary to test this theory.
We chose the anterior circulation model [18] over the
endovascular perforation model and acknowledge that
there are limitations; however, we felt that the strengths
of the anterior circulation model outweighed the weak-
nesses. In the anterior circulation model, the increase in
intracranial pressure is less severe. Additionally, blood
entering the subarachnoid space of a mouse in this
method would be that of a donor mouse. On the other
hand, the endovascular perforation method better ap-
proximates the intracranial pressure crises that can
occur in SAH patients.
However, the anterior circulation model has a number
of advantages over the endovascular perforation method.
First, the amount of blood (60 μl) injected into each
mouse, and the resultant increased intracranial pressure
is consistent between mice. Because of this, we feel that
results obtained using the anterior circulation method
are better reproduced. Further, the lower mortality seen
with this model is helpful when performing experiments
on conditional knockouts, as well as dual injection pro-
cedures required for SAH and intracerebroventricular
DFX. We have used the anterior circulation method in
our past research and believe it to be suitable for our
current research interests as well.
In stroke patients, DFX reduced serum markers of oxi-
dative stress and increased antioxidant species [49],
while in ICH patients, phase-I testing revealed DFX to
be safe and well tolerated [50]. Currently, promising
clinical trials investigating the use of DFX for ICH are
underway [51]. Our research provides a platform for lin-
ear translation of DFX treatment into the human SAH
population. Our data show that intracerebroventricular
DFX yields the greatest neuroprotection via a mechan-
ism that is dependent on microglial HO-1 and possibly a
protective microglial polarization. Given the fact that
high-grade SAH patients will have an external
ventriculostomy drain (EVD) placed at admission, a
feasibility study for the use of intracerebroventricular
DFX in these patients should be explored in the fu-
ture. Furthermore, monitoring patient HO-1 expres-
sion during DFX treatment for hemorrhagic stroke
may help clinicians identify patients that are more
likely to respond to treatment.
Conclusions
ICV DFX treatment provides superior neuroprotection
in a mouse model of SAH. Our results indicate that the
mechanisms by which DFX provides neuroprotection
after SAH may involve microglial/macrophage HO-1 ex-
pression. Monitoring patient HO-1 expression during
DFX treatment for hemorrhagic stroke may help clini-
cians identify patients that are more likely to respond to
treatment.
Additional file
Additional file 1: Figure S1. Flow cytometry gating method for
identification of hematogenous and cerebral cells. (TIF 9440KB)
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Fig. 5 Macrophage/microglial HO-1 is critical to ICV DFX neuroprotection and improvement in cognitive outcome after SAH—Cortical and
hippocampal damage as well as cognitive outcome were measured after SAH induction and ICV DFX treatment in the following HO-1 conditional
knockouts: Hmox1fl/fl, LyzMCre:Hmox1fl/fl, and NesCre:Hmox1fl/fl. a Representative confocal images of cortical and hippocampus sections for each
genotype after SAH on POD7. Each color represents the following: green = HO-1; red = Iba-1/microglia; yellow= overlap of green and red/co-localization
of HO-1 and microglia; blue = DAPI nuclei counterstain. All scale bars= 20 μm. b The percent quantification of co-localization per high-powered field
for each genotype’s Z-stacked images. Co-localization percentage was obtained by dividing the total number of yellow-positive cells by the total
number of DAPI-positive cells. LyzMCre:Hmox1fl/fl SAH mice showed the least HO-1/Iba-1 co-localization percentage in both the cortex and
hippocampus as compared to Hmox1fl/fl and NesCre:Hmox1fl/fl SAH mice (two-way ANOVA P < 0.05; *P < 0.05; n = 4 per group). c TUNEL (red) stained
images of cortical and hippocampal sections from each group with DAPI (blue) nuclei counterstain on POD7 (scale bar= 20 μm). d Quantification of
TUNEL-positive cells from each treated genotype. Both Hmox1fl/fl and NesCre:Hmox1fl/fl SAH mice showed significantly less cortical and hippocampal
damage than LyzMCre:Hmox1fl/fl SAH mice when treated with ICV DFX. (Two-way ANOVA P < 0.05; *P < 0.05 between groups for cortical damage and
**P < 0.05 between groups for hippocampal damage; n = 4 per group). e Morris water maze testing of HO-1 conditional knockout cognition after SAH
induction and ICV DFX treatment. Inset, bar graph of data for POD4, 5, and 7 shows both Hmox1fl/fl and NesCre:Hmox1fl/fl SAH mice performed
significantly better than LyzMCre:Hmox1fl/fl SAH mice on POD5 and 7 when treated with ICV DFX, with a similar trend on POD4. (Two-way ANOVA
P < 0.05;#P = 0.07 between groups on POD4; *P < 0.05 between groups on POD5 and 7; n = 4 per group)
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